Loading...
XNAS
IMNN
Market cap5mUSD
Jul 09, Last price  
2.01USD
1D
-2.43%
1Q
-31.16%
Jan 2017
-99.76%
Name

Imunon Inc

Chart & Performance

D1W1MN
XNAS:IMNN chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
67.02%
Rev. gr., 5y
0.00%
Revenues
0k
11,250,81702,500,000002,000,0000500,000500,000500,000500,000500,000500,000500,000500,000500,000500,000000
Net income
-14m
L-22.15%
-7,584,23035,349,057-11,786,215-15,193,000-18,818,435-23,222,678-26,568,000-8,251,358-25,494,273-22,461,084-22,053,726-20,402,176-11,883,359-16,851,533-21,483,561-20,769,250-35,898,234-19,514,977-18,620,242-14,495,000
CFO
-14m
L-26.30%
-7,232,790-9,582,7852,281,263-930,331-13,367,389-22,742,437-22,144,193-9,525,276-21,353,020-20,830,563-18,379,364-16,642,076-7,041,686-20,258,982-15,618,676-16,223,603-23,096,895-19,022,148-18,854,970-13,896,624

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Imunon, Inc. is a biotechnology enterprise operating at the clinical development stage, dedicated to the advancement and commercialization of innovative DNA-centric immunotherapeutic agents, vaccines, and targeted chemotherapy treatments. Its product pipeline prominently features GEN-1, a DNA-based immunotherapy specifically designed for the localized management of ovarian cancer. Alongside this, the company is developing ThermoDox, a proprietary liposomal formulation of doxorubicin that is activated by heat, currently being explored for various oncological indications. Beyond its specific product candidates, Imunon also possesses two early-stage platform technologies, which serve as foundational tools for crafting additional nucleic acid-based immunotherapies, vaccines, and diverse anti-cancer DNA or RNA therapeutics. Founded in 1982 and headquartered in Lawrenceville, New Jersey, the company was formerly recognized as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
URL
https://imunon.com/
IPO date
Oct 27, 1993
Employees
31
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT